Research Topics
Genomes and Genes | Scott M DehmSummaryAffiliation: Mayo Clinic Country: USA Publications
| Collaborators
|
Detail Information
Publications
SRC proximal and core promoter elements dictate TAF1 dependence and transcriptional repression by histone deacetylase inhibitorsScott M Dehm
Department of Biochemistry, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5E5, Canada
Mol Cell Biol 24:2296-307. 2004....
SRC gene expression in human cancer: the role of transcriptional activationScott M Dehm
Department of Biochemistry, University of Saskatchewan, Saskatoon, Canada
Biochem Cell Biol 82:263-74. 2004..Analysis of the mechanisms behind HDAC inhibitor mediated repression could be utilized in the future to specifically inhibit SRC gene expression in human cancer...- Regulation of alternative SRC promoter usage in HepG2 hepatocellular carcinoma cellsScott M Dehm
Cancer Research Unit, Health Research Division, Saskatchewan Cancer Agency, Saskatoon, Canada
Gene 337:141-50. 2004..This approach identified a HepG2-specific DH site that displayed activating potential towards the SRC1alpha promoter. These results thus provide important insight to the mechanism of SRC transcriptional activation in liver cancer cells... - Regulation of androgen receptor signaling in prostate cancerScott M Dehm
Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
Expert Rev Anticancer Ther 5:63-74. 2005..How these mechanisms of androgen receptor activation could be targeted in this advanced stage of the disease is also discussed... - Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistanceScott M Dehm
Department of Urology and Biochemistry, Mayo Clinical College of Medicine, Rochester, Minnesota, USA
Cancer Res 68:5469-77. 2008..Together, our data describe a simple and effective mechanism by which PCa cells can synthesize a constitutively active AR and thus circumvent androgen ablation... - Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cellsScott M Dehm
Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
J Biol Chem 281:27882-93. 2006..Our data thus demonstrate that the AR can inappropriately activate transcription in ADI PCa cells via mechanisms that are resistant to castration and AR antagonism, the two modes of androgen ablation used to treat advanced PCa... - Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosisKristin A Raclaw
Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Prostate 68:1696-706. 2008..In the current study, we examined the androgenic regulation of FLIP and its contribution to protecting prostate cancer cells from death receptor-mediated apoptosis... - Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cellsScott M Dehm
Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Cancer Res 67:10067-77. 2007..These data show that ligand-dependent and ligand-independent AR activation rely on fundamentally distinct mechanisms, and define WxxLF as the major transactivation motif within the AR TAU5 domain... - Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancerHannelore V Heemers
Department of Urology Research Biochemistry, Mayo Clinic, Rochester, MN 55905, USA
Cancer Res 67:10592-9. 2007..These results suggest a novel indirect mechanism of androgen action on FHL2 expression and provide evidence that SRF is an important determinant of AR action in prostate cancer cells... - p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6Jose D Debes
Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Cancer Res 65:5965-73. 2005.... - Androgen receptor structural and functional elements: role and regulation in prostate cancerScott M Dehm
Departments of Urology and Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, Minnesota 55905, USA
Mol Endocrinol 21:2855-63. 2007..A comprehensive understanding of the role and functional relationships between these AR domains could lead to the development of novel AR-directed therapies for prostate cancer... - Molecular regulation of androgen action in prostate cancerScott M Dehm
Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
J Cell Biochem 99:333-44. 2006..We will also summarize several recent studies that have attempted to unravel how these genes are deregulated in androgen depletion independent prostate cancer... - The modification of Sp3 isoforms by SUMOylation has differential effects on the SRC1A promoterDanielle J P Ellis
Cancer Research Unit, Health Research Division, Saskatchewan Cancer Agency, Saskatoon, SK, Canada
Gene 379:68-78. 2006..These results provide new insights into the complexity of Sp3 mediated transcription which appears to be highly dependent on the isoform bound, SUMOylation status and the promoter context... - The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylasesCalley L Kostyniuk
Department of Biochemistry, University of Saskatchewan, Saskatoon SK, Canada S7N 5E5
Oncogene 21:6340-7. 2002..Our finding that sodium butyrate and Trichostatin A inhibit both SRC promoters suggest this oncogene may be a major target of these agents, and may explain in part their anti-cancer activity...